News

Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...
Eli Lilly strikes $1.3 billion deal to buy gene-editing biotech Verve Therapeutics, companies say
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...
This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid
Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company ...
pharmaphorum59m
Is Lilly about to swoop on Verve Therapeutics?
In April, Verve tweaked the development of the first PCSK9 inhibitor in its programme (VERVE-101) after a trial revealed ...
This five-star fund manager says even smart investors have been missing the greatest theme of our time
The news these days is distracting even for Wall Street's best, like Alger Funds' star stock picker and portfolio manager Patrick Kelly, who kept watch on Iran-Israel headlines while sharing secrets ...
Tokenist42m
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
The rumored acquisition represents a natural progression of the existing partnership between Eli Lilly and Verve Therapeutics that began in mid-2023. Initially focused on advancing Verve’s in vivo ...